� |
� |
� |
�
|
AN ACT
|
�
|
relating to enrollment and participation in certain research |
�
|
programs of certain children in foster care. |
�
|
�������BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
�
|
�������SECTION�1.��Section 266.001, Family Code, as added by |
�
|
Chapter 268, Acts of the 79th Legislature, Regular Session, 2005, |
�
|
is amended by adding Subdivisions (2-a) and (4-a) to read as |
�
|
follows: |
�
|
�������������(2-a)��"Drug research program" means any clinical |
�
|
trial, clinical investigation, drug study, or active medical or |
�
|
clinical research that has been approved by an institutional review |
�
|
board in accordance with the standards provided in the Code of |
�
|
Federal Regulations, 45 C.F.R. Sections 46.404 through 46.407, |
�
|
regarding: |
�
|
�������������������(A)��an investigational new drug; or |
�
|
�������������������(B)��the efficacy of an approved drug. |
�
|
�������������(4-a)��"Investigational new drug" has the meaning |
�
|
assigned by 21 C.F.R. Section 312.3(b). |
�
|
�������SECTION�2.��Subchapter A, Chapter 266, Family Code, as added |
�
|
by Chapter 268, Acts of the 79th Legislature, Regular Session, |
�
|
2005, is amended by adding Section 266.0041 to read as follows: |
�
|
�������Sec.�266.0041.��ENROLLMENT AND PARTICIPATION IN CERTAIN |
�
|
RESEARCH PROGRAMS. �(a)���Notwithstanding Section 266.004, a person |
�
|
may not authorize the enrollment of a foster child or consent to the |
�
|
participation of a foster child in a drug research program without a |
�
|
court order as provided by this section, unless the person is the |
�
|
foster child's parent and the person has been authorized by the |
�
|
court to make medical decisions for the foster child in accordance |
�
|
with Section 266.004. |
�
|
�������(b)��Before issuing an order authorizing the enrollment or |
�
|
participation of a foster child in a drug research program, the |
�
|
court must: |
�
|
�������������(1)��appoint an independent medical advocate; |
�
|
�������������(2)��review the report filed by the independent medical |
�
|
advocate regarding the advocate's opinion and recommendations |
�
|
concerning the foster child's enrollment and participation in the |
�
|
drug research program; |
�
|
�������������(3)��consider whether the person conducting the drug |
�
|
research program: |
�
|
�������������������(A)��informed the foster child in a |
�
|
developmentally appropriate manner of the expected benefits of the |
�
|
drug research program, any potential side effects, and any |
�
|
available alternative treatments and received the foster child's |
�
|
assent to enroll the child to participate in the drug research |
�
|
program as required by the Code of Federal Regulations, 45 C.F.R. |
�
|
Section 46.408; or |
�
|
�������������������(B)��received informed consent in accordance with |
�
|
Subsection (h); and |
�
|
�������������(4)��determine whether enrollment and participation in |
�
|
the drug research program is in the foster child's best interest and |
�
|
determine that the enrollment and participation in the drug |
�
|
research program will not interfere with the appropriate medical |
�
|
care of the foster child. |
�
|
�������(c)��An independent medical advocate appointed under |
�
|
Subsection (b) is not a party to the suit but may: |
�
|
�������������(1)��conduct an investigation regarding the foster |
�
|
child's participation in a drug research program to the extent that |
�
|
the advocate considers necessary to determine: |
�
|
�������������������(A)��whether the foster child assented to or |
�
|
provided informed consent to the child's enrollment and |
�
|
participation in the drug research program; and |
�
|
�������������������(B)��the best interest of the child for whom the |
�
|
advocate is appointed; and |
�
|
�������������(2)��obtain and review copies of the foster child's |
�
|
relevant medical and psychological records and information |
�
|
describing the risks and benefits of the child's enrollment and |
�
|
participation in the drug research program. |
�
|
�������(d)��An independent medical advocate shall, within a |
�
|
reasonable time after the appointment, interview: |
�
|
�������������(1)��the foster child in a developmentally appropriate |
�
|
manner, if the child is four years of age or older; |
�
|
�������������(2)��the foster child's parent, if the parent is |
�
|
entitled to notification under Section 266.005; |
�
|
�������������(3)��an advocate appointed by an institutional review |
�
|
board in accordance with the Code of Federal Regulations, 45 C.F.R. |
�
|
Section 46.409(b), if an advocate has been appointed; |
�
|
�������������(4)��the medical team treating the foster child as well |
�
|
as the medical team conducting the drug research program; and |
�
|
�������������(5)��each individual who has significant knowledge of |
�
|
the foster child's medical history and condition, including any |
�
|
foster parent of the child. |
�
|
�������(e)��After reviewing the information collected under |
�
|
Subsections (c) and (d), the independent medical advocate shall: |
�
|
�������������(1)��submit a report to the court presenting the |
�
|
advocate's opinion and recommendation regarding whether: |
�
|
�������������������(A)��the foster child assented to or provided |
�
|
informed consent to the child's enrollment and participation in the |
�
|
drug research program; and |
�
|
�������������������(B)��the foster child's best interest is served by |
�
|
enrollment and participation in the drug research program; and |
�
|
�������������(2)��at the request of the court, testify regarding the |
�
|
basis for the advocate's opinion and recommendation concerning the |
�
|
foster child's enrollment and participation in a drug research |
�
|
program. |
�
|
�������(f)��The court may appoint any person eligible to serve as |
�
|
the foster child's guardian ad litem, as defined by Section |
�
|
107.001, as the independent medical advocate, including a physician |
�
|
or nurse or an attorney who has experience in medical and health |
�
|
care, except that a foster parent, employee of a substitute care |
�
|
provider or child placing agency providing care for the foster |
�
|
child, representative of the department, medical professional |
�
|
affiliated with the drug research program, independent medical |
�
|
advocate appointed by an institutional review board, or any person |
�
|
the court determines has a conflict of interest may not serve as the |
�
|
foster child's independent medical advocate. |
�
|
�������(g)��A person otherwise authorized to consent to medical care |
�
|
for a foster child may petition the court for an order permitting |
�
|
the enrollment and participation of a foster child in a drug |
�
|
research program under this section. |
�
|
�������(h)��Before a foster child, who is at least 16 years of age |
�
|
and has been determined to have the capacity to consent to medical |
�
|
care in accordance with Section 266.010, may be enrolled to |
�
|
participate in a drug research program, the person conducting the |
�
|
drug research program must: |
�
|
�������������(1)��inform the foster child in a developmentally |
�
|
appropriate manner of the expected benefits of participation in the |
�
|
drug research program, any potential side effects, and any |
�
|
available alternative treatments; and |
�
|
�������������(2)��receive written informed consent to enroll the |
�
|
foster child for participation in the drug research program. |
�
|
�������(i)��A court may render an order approving the enrollment or |
�
|
participation of a foster child in a drug research program |
�
|
involving an investigational new drug before appointing an |
�
|
independent medical advocate if: |
�
|
�������������(1)��a physician recommends the foster child's |
�
|
enrollment or participation in the drug research program to provide |
�
|
the foster child with treatment that will prevent the death or |
�
|
serious injury of the child; and |
�
|
�������������(2)��the court determines that the foster child needs |
�
|
the treatment before an independent medical advocate could complete |
�
|
an investigation in accordance with this section. |
�
|
�������(j)��As soon as practicable after issuing an order under |
�
|
Subsection (i), the court shall appoint an independent medical |
�
|
advocate to complete a full investigation of the foster child's |
�
|
enrollment and participation in the drug research program in |
�
|
accordance with this section. |
�
|
�������(k)��This section does not apply to: |
�
|
�������������(1)��a drug research study regarding the efficacy of an |
�
|
approved drug that is based only on medical records, claims data, or |
�
|
outcome data, including outcome data gathered through interviews |
�
|
with a child, caregiver of a child, or a child's treating |
�
|
professional; |
�
|
�������������(2)��a retrospective drug research study based only on |
�
|
medical records, claims data, or outcome data; or |
�
|
�������������(3)��the treatment of a foster child with an |
�
|
investigational new drug that does not require the child's |
�
|
enrollment or participation in a drug research program. |
�
|
�������(l)��The department shall annually submit to the governor, |
�
|
lieutenant governor, speaker of the house of representatives, and |
�
|
the relevant committees in both houses of the legislature, a report |
�
|
regarding: |
�
|
�������������(1)��the number of foster children who enrolled or |
�
|
participated in a drug research program during the previous year; |
�
|
�������������(2)��the purpose of each drug research program in which |
�
|
a foster child was enrolled or participated; and |
�
|
�������������(3)��the number of foster children for whom an order was |
�
|
issued under Subsection (i). |
�
|
�������(m) A foster parent or any other person may not receive a |
�
|
financial incentive or any other benefit for recommending or |
�
|
consenting to the enrollment and participation of a foster child in |
�
|
a drug research program. |
�
|
�������SECTION�3.��Subsection (b), Section 266.005, Family Code, as |
�
|
added by Chapter 268, Acts of the 79th Legislature, Regular |
�
|
Session, 2005, is amended to read as follows: |
�
|
�������(b)��Except as provided by Subsection (c), the department |
�
|
shall make reasonable efforts to notify the child's parents within |
�
|
24 hours of: |
�
|
�������������(1)��a significant medical condition involving a foster |
�
|
child; and |
�
|
�������������(2)��the enrollment or participation of a foster child |
�
|
in a drug research program under Section 266.0041. |
�
|
�������SECTION�4.��The change in law made by this Act by the |
�
|
enactment of Section 266.0041, Family Code, applies only to the |
�
|
enrollment and participation of a foster child in a drug research |
�
|
program on or after the effective date of this Act. A foster child |
�
|
enrolled or participating in a drug research program before the |
�
|
effective date of this Act is governed by the law in effect when the |
�
|
foster child was enrolled or began participating in the drug |
�
|
research program, and the former law is continued in effect for that |
�
|
purpose. |
�
|
�������SECTION�5.��This Act takes effect September 1, 2007. |
�
|
|
�
|
|
� |
� |
� |
� |
______________________________ |
______________________________ |
� |
���President of the Senate |
Speaker of the House����� |
� |
�
|
�������I hereby certify that S.B.�No.�450 passed the Senate on |
�
|
April�17,�2007, by the following vote: Yeas�30, Nays�0; and that |
�
|
the Senate concurred in House amendment on May�21,�2007, by the |
�
|
following vote: Yeas�31, Nays�0. |
�
|
|
� |
� |
______________________________ |
� |
Secretary of the Senate���� |
� |
�
|
�������I hereby certify that S.B.�No.�450 passed the House, with |
�
|
amendment, on May�16,�2007, by the following vote: Yeas�142, |
�
|
Nays�0, one present not voting. |
�
|
|
� |
� |
______________________________ |
� |
Chief Clerk of the House��� |
� |
�
|
|
� |
�
|
Approved: |
�
|
|
�
|
______________________________� |
�
|
������������Date |
�
|
|
�
|
|
�
|
______________________________� |
�
|
����������Governor |